Medicinal Products

35. Deputy Pádraig O'Sullivan asked the Minister for Health if she will provide an appraisal of the work that has been carried out on a review of the drugs reimbursement scheme and the creation of an early access scheme as per Programme for Government commitments; and if she will make a statement on the matter. [17474/26]

60. Deputy Peter Roche asked the Minister for Health when she intends to commence a review of the reimbursement process, as committed to in the Programme for Government; whether such a review will specifically include the way in which orphan medicines are assessed and reimbursed; and if she will make a statement on the matter. [17622/26]

75. Deputy Catherine Ardagh asked the Minister for Health her plans to expand access to weight loss medications given the health and societal costs of obesity; and if she will make a statement on the matter. [17500/26]

101. Deputy Aindrias Moynihan asked the Minister for Health the up-to-date position on a medication (details supplied) being available on the drugs payment scheme; and if she will make a statement on the matter. [17677/26]

119. Deputy Catherine Ardagh asked the Minister for Health her plans to review current regulations regarding the prescription of melatonin; and if she will make a statement on the matter. [17499/26]

120. Deputy Pádraig Rice asked the Minister for Health to provide an update on the delivery of the programme for Government commitment to continue to extend access to free contraception; the work carried out to date; the timeline she is working towards in expanding the scheme; and if she will make a statement on the matter. [17723/26]

525. Deputy Conor Sheehan asked the Minister for Health the specific steps being taken to ensure the HSE considers the time-critical nature of Friedreich’s ataxia during the current price negotiations for Skyclarys, the only drug approved for treatment of this condition, given the 570 days since the application for use was lodged and the rapid progression of the disease in sufferers; and if she wi…

526. Deputy Conor Sheehan asked the Minister for Health the way in which the commitments in the National Rare Disease Strategy 2025 – 2030 are being applied to the approval process for the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17918/26]

527. Deputy Conor Sheehan asked the Minister for Health the way in which the 2026 IPHA Framework Agreement on access to new and innovative medicines which aims for a 180-day decision timeline is being applied to the drug Skyclarys used to treat Friedrich's ataxia to prevent further delays in addressing the unmet need of sufferers; and if she will make a statement on the matter. [17919/26]

538. Deputy Alan Kelly asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; and if she will make a statement on …

539. Deputy Alan Kelly asked the Minister for Health her views on whether the current delay regarding the Skyclarys reimbursement negotiations aligns with the "equitable access" promised in the newly launched National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [17959/26]

569. Deputy Donna McGettigan asked the Minister for Health to make acarizax available under the drug payment scheme; to recommend a course of action for a family facing unmanageable prescription charges due to having to pay for it, in addition to other medications which are on the drug payment scheme, but still cost €80; and if she will make a statement on the matter. [18051/26]

590. Deputy Charles Ward asked the Minister for Health whether a chairperson has been assigned to the cannabis access review panel; if so, whether the Minister could advise the person chosen; if not, when will this position be filled so that work on the review can be commenced; and if she will make a statement on the matter. [18163/26]

248. Deputy William Aird asked the Minister for Health if she will include acarizax on the reimbursement list of medicines; and if she will make a statement on the matter. [17270/26]

249. Deputy Ciarán Ahern asked the Minister for Health the reason Skyclarys has not yet been approved for reimbursement despite being authorised for use by the European Medicines Agency; and if she will make a statement on the matter. [17273/26]

250. Deputy Ciarán Ahern asked the Minister for Health the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [17274/26]

251. Deputy Ciarán Ahern asked the Minister for Health the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement which aims for a 180-day decision timeline are being applied to the HSE’s consideration of Skyclarys, to prevent further delays; and if she will make a statement on the matter. [17275/26]

257. Deputy Catherine Ardagh asked the Minister for Health the reason all melatonin products require a prescription in Ireland; if she will consider allowing availability without prescription for products with a lower dosage of the product (details supplied) in order that it could be classified as a food supplement; and if she will make a statement on the matter. [17309/26]

260. Deputy Ryan O'Meara asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for this progressive disease, which can currently be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; if the current delay aligns with t…

274. Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; and if she will make a statement on the matter. [17394/26]

275. Deputy Johnny Guirke asked the Minister for Health regarding the reimbursement of Skyclarys (omaveloxolone), the only approved treatment for Friedreich’s Ataxia (details supplied), the way in which the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) are being applied to this specific case, to preven…

292. Deputy Shay Brennan asked the Minister for Health the specific steps being taken to ensure the HSE considers the “time-critical” nature of FA during the current price negotiations for Skyclarys. [17453/26]

293. Deputy Shay Brennan asked the Minister for Health the commitments in the National Rare Disease Strategy 2025-2030 and the 2026 IPHA Framework Agreement (which aims for a 180-day decision timeline) which are being applied to a specific case, to prevent further delays in addressing the ‘unmet need’ with FA. [17454/26]

349. Deputy Michael Lowry asked the Minister for Health if she will intervene to ensure that the HSE prioritises a conclusion to the Skyclarys reimbursement negotiations, given that it is the only available treatment for a progressive disease (details supplied) which currently can be classed as having an ‘unmet need’ as outlined in the National Rare Disease Strategy 2025 – 2030; her views on wheth…

350. Deputy Willie O'Dea asked the Minister for Health if she will provide an update on the process to allow for the reimbursement of Skyclarys, the only approved treatment for Friedreich’s Ataxia (FA); the specific steps being taken to ensure the HSE considers the "time-critical" nature of FA during the current price negotiations for Skyclarys; the way in which the commitments in the National Rar…